Cardinal Health, Inc. CAH
Healthcare · Medical Distribution · United States · S&P 500
Based on the available data, Cardinal Health, Inc. gets an algorithmic score of 53/100. It trades at 223.91 $, with a bullish technical trend (RSI 40.4) and 29.3% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Attractive free-cash-flow yield (8.7%).
- Low beta (0.23): defensive profile.
- Meaningful dividend (92.00%).
Weaknesses
- Thin net margin (0.7%): vulnerable to costs.
Fundamentals
| P/E | 30.97 |
| Forward P/E | 15.93 |
| PEG | 1.11 |
| P/B | -18.10 |
| EV/EBITDA | 13.52 |
| P/S | 0.20 |
| ROA % | 3.72 |
| Gross margin % | 3.84 |
| Operating margin % | 1.33 |
| Net margin % | 0.67 |
| Revenue growth % (y/y) | 5.80 |
| Earnings growth % (y/y) | 68.80 |
| Revenue CAGR % | 7.44 |
| Earnings CAGR % | 73.18 |
| Current ratio | 0.88 |
| FCF yield % | 8.73 |
| Dividend yield % | 92.00 |
| Payout % | 28.33 |
Returns
| 1 month | -4.5 % |
| 3 months | -5.5 % |
| 6 months | +9.0 % |
| YTD | +9.3 % |
| 1 year | +47.2 % |
| 3 years | +163.6 % |
| 5 years | +389.2 % |
Risk
| 1-year volatility | 29.3 % |
| Beta | 0.23 |
| 5-year max drawdown | -20.9 % |
| Sharpe 1A | 1.33 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.